Pravastatin Applications in Preeclampsia Management

Preeclampsia is a multisystem hypertensive disorder of pregnancy characterised by endothelial dysfunction, exaggerated inflammatory responses and an imbalance between angiogenic and anti-angiogenic factors. Pravastatin, a hydrophilic inhibitor of HMG-CoA reductase, has attracted interest for its pleiotropic effects beyond lipid lowering. By upregulating endothelial nitric oxide synthase and restoring angiogenic balance, pravastatin counteracts the excess of soluble fms-like tyrosine kinase-1 relative to placental growth factor. It also attenuates oxidative stress, reverses pro-inflammatory adipokine overexpression and normalises matrix remodelling enzymes in the placenta. Preclinical models and early clinical trials suggest pravastatin may prevent or mitigate the progression of preeclampsia without adverse fetal effects, offering a potential pharmacological approach to a condition that currently has no cure other than delivery.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Pravastatin Applications in Preeclampsia Management publication trend

The graph below shows the total number of articles in pravastatin applications in preeclampsia management across all publications each year (not limited to Nature Index journals).

Technical terms

Preeclampsia: A pregnancy disorder with hypertension and organ dysfunction due to placental and vascular pathology.

Statin: A drug class inhibiting HMG-CoA reductase, primarily used to lower cholesterol but with vascular and anti-inflammatory effects.

sFlt-1/PlGF ratio: The balance between soluble fms-like tyrosine kinase-1 and placental growth factor, indicative of angiogenic status in pregnancy.

Chemerin: An adipokine involved in inflammation and vascular tone, elevated in preeclampsia.

Matrix metalloproteinase-2 (MMP-2): An enzyme that degrades extracellular matrix components, activated by oxidative stress.

EGFL7: A protein involved in endothelial cell function and angiogenesis, implicated in placental development.

Nitric oxide (NO): A vasodilator produced by endothelial nitric oxide synthase, critical for vascular homeostasis in pregnancy.

References

1. Statins Prevent the Deleterious Consequences of Placental Chemerin Upregulation in Preeclampsia. Hypertension (2024).
2. Effect of Pravastatin on Placental Expression of Epidermal Growth Factor-like Domain 7 in Early-Onset Pre-Eclampsia: A New Potential Mechanism of Action. Biomedicines (2024).
3. Pravastatin Prevents Increases in Activity of Metalloproteinase-2 and Oxidative Stress, and Enhances Endothelium-Derived Nitric Oxide-Dependent Vasodilation in Gestational Hypertension. Antioxidants (2023).
4. Pravastatin for early‐onset pre‐eclampsia: a randomised, blinded, placebo‐controlled trial. BJOG An International Journal of Obstetrics & Gynaecology (2019).